Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 2,214 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Genes Clear all
Terminated Phase 1Phase 2 Interventional Results available

Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer

NCT00924287
View directory record Official record
Conditions
Metastatic Cancer
Interventions
in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin, Cyclophosphamide, Fludarabine, Mesna
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 28, 2026, 2:32 AM EDT
Active, not recruiting Phase 1 Interventional

ATA-200 Gene Therapy Trial in Patients With LGMDR5

NCT05973630
View directory record Official record
Conditions
LGMD2C
Interventions
ATA-200
Biological
Lead sponsor
Atamyo Therapeutics
Industry
Eligibility
6 Years to 13 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Gainsville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pharmacogenetics of Cannabinoid Response

NCT00678730
View directory record Official record
Conditions
COMT Gene Polymorphism
Interventions
delta 9 tetrahydrocannabinol
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 28, 2026, 2:32 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study of Treatment and Metabolism in Patients With Urea Cycle Disorders

NCT00004307
View directory record Official record
Conditions
Amino Acid Metabolism, Inborn Errors
Interventions
Protein and calorie controlled diet, Ornithine transcarbamylase vector
Behavioral · Genetic
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
6 Months to 64 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational Results available

Detection of Microorganisms and Antibiotic Resistance Genes Using the Curetis Unyvero LRT55 Application

NCT01922024
View directory record Official record
Conditions
Pneumonia
Interventions
LRT55 Testing
Device
Lead sponsor
Curetis GmbH
Industry
Eligibility
18 Years and older
Enrollment
2,124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting Phase 2 Interventional

Tirzepatide for Treatment of CCCA

NCT07734870
View directory record Official record
Conditions
Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions
Tirzepatide
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

NCT03316560
View directory record Official record
Conditions
X-Linked Retinitis Pigmentosa
Interventions
rAAV2tYF-GRK1-RPGR
Biological
Lead sponsor
Beacon Therapeutics
Industry
Eligibility
6 Years to 50 Years · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
4
States / cities
Durham, North Carolina • Cincinnati, Ohio • Portland, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 1 Interventional

Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations

NCT01948297
View directory record Official record
Conditions
Solid Tumours
Interventions
Debio1347 (CH5183284)
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Genetic Analysis of Attention Deficit Hyperactivity Disorder (ADHD)

NCT00046059
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
7 Years to 110 Years
Enrollment
3,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
2
States / cities
Orange, California • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Environmental Exposures on the Egg Fertilizing Ability of Human Sperm

NCT00012480
View directory record Official record
Conditions
Male Infertility, Testicular Diseases, Urologic and Male Genital Diseases, Lead Poisoning
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
21 Years to 55 Years · Male only
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
3
States / cities
Los Angeles, California • Manhasset, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

NCT03733496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years and older
Enrollment
14 participants
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C

NCT02006823
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2014 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 1 Interventional

Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

NCT00085462
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
aldesleukin, filgrastim, gp100-fowlpox vaccine, therapeutic autologous lymphocytes, therapeutic tumor infiltrating lymphocytes, cyclophosphamide, fludarabine phosphate
Biological · Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting Phase 2 Interventional

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

NCT06528691
View directory record Official record
Conditions
High Grade Glioma, CNS Tumor
Interventions
Entrectinib, Cyclophosphamide, Etoposide, Carboplatin, G-CSF, Pegfilgrastim, Surgery
Drug · Biological · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 3 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

NCT03365882
View directory record Official record
Conditions
Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage III Colon Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7
Interventions
Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis, Pertuzumab, Trastuzumab, HER-2 testing
Biological · Drug · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
786
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 501 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families

NCT00341627
View directory record Official record
Conditions
Chordoma
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 110 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
2
States / cities
Iowa City, Iowa • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 28, 2026, 2:32 AM EDT
Completed No phase listed Observational

Gene Expression Profiles in Patients With Metastatic Pancreatic Cancer

NCT00897741
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
microarray analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2014 · Synced Oct 28, 2026, 2:32 AM EDT
Withdrawn Phase 1Phase 2 Interventional

CISH Inactivated TILs in the Treatment of NSCLC

NCT05566223
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Large Cell Lung Cancer
Interventions
Fludarabine, Cyclophosphamide, CISH Inactivated TIL, Aldesleukin, Pembrolizumab
Drug · Biological
Lead sponsor
Intima Bioscience, Inc.
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Duarte, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated No phase listed Observational Results available

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

NCT00898937
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, breast biopsy
Genetic · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Not applicable Interventional

IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

NCT01727531
View directory record Official record
Conditions
Brain Metastasis
Interventions
Chloroquine diphosphate
Drug
Lead sponsor
Main Line Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Wynnewood, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 28, 2026, 2:32 AM EDT
Recruiting Phase 1Phase 2 Interventional

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

NCT06161519
View directory record Official record
Conditions
Glioma, Medulloblastoma, Ependymoma, Glioblastoma
Interventions
PLX038
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 2:32 AM EDT
Completed Phase 2 Interventional Results available

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

NCT02953457
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Olaparib, Tremelimumab
Biological · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
2
States / cities
Buffalo, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 1 Interventional

Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM

NCT03283631
View directory record Official record
Conditions
Recurrent Glioblastoma, Recurrent Gliosarcoma
Interventions
EGFRvIII-CARs
Biological
Lead sponsor
Gary Archer Ph.D.
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 28, 2026, 2:32 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A

NCT04541628
View directory record Official record
Conditions
Hemophilia A
Interventions
SIG-001
Combination Product
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Oct 28, 2026, 2:32 AM EDT